Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 2/20 | 0.35 |
| ▸ | MDM4 | O15151 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10045805 | 0.95 | TNF (0.35) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL10045809 | 0.93 | TNF (0.34) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL800983 | 0.89 | TNF (0.33) | TNF | |
| SCHEMBL800894 | 0.83 | MDM4 (0.33) | TNFMDM4TP53CASP3MDM2 | |
| SCHEMBL800437 | 0.81 | MDM4 (0.34) | MDM4TP53CASP3HDAC1HDAC2 | |
| SCHEMBL10045807 | 0.75 | HDAC1 (0.41) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL3366333 | 0.66 | TNF (0.59) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL120685 | 0.66 | TNF (0.59) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL31186620 | 0.66 | TNF (0.59) | TNFMDM4TP53CASP3HDAC1 | |
| SCHEMBL29398946 | 0.66 | TNF (0.59) | TNFMDM4TP53CASP3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093235-B2 | Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2012-01-10 | — | — | US | disclosed |
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156627-A1 | THERAPEUTIC COMPOUNDS | TOP2B, DDB1, RECQL | TNF 4654/4885MDM4 579/4885TP53 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.